FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4236430596> ?p ?o ?g. }

• W4236430596 endingPage "S296" @default.
• W4236430596 startingPage "S296" @default.
• W4236430596 abstract "To estimate the cost per responder of psoriatic arthritis (PsA) treatment with secukinumab versus etanercept biosimilar from the Portuguese National Health System (NHS). The cost per responder for each treatment was estimated by dividing the drug acquisition cost of a 24-week course of treatment with its response rate based on the American College of Rheumatology outcomes (ACR20/50/70). Drug acquisition costs were estimated using 2018 official prices from the perspective of the NHS; number of doses required for the course of treatment were defined according to the approved EU label. Response rates were estimated using a matching-adjusted indirect comparison (MAIC) based on the data from FUTURE 2 and ETN clinical trials of secukinumab and etanercept, respectively. MAIC analysis matched the age, weight, race and gender, and other relevant baseline characteristics, such as PASI score, HAQ-DI score, methotrexate use, psoriasis on ≥3% of BSA, dactylitis, enthesitis, and previous use of anti-TNF. The predicted ACR20, 50 and 70 response rates were 73.3%, 52.4% and 30.1% for secukinumab 150mg, 74.4%, 45.7% and 25.3% for secukinumab 300mg and 54.4%, 42.2% and 10.0% for etanercept biosimilar 50mg, respectively. The 24-week cost of secukinumab 150mg/300mg was €3,790/€7,581 versus €3,312 for etanercept biosimilar. Estimates of the cost per ACR20 responder were €5,171, €10,189 and €6,088, cost per ACR50 responder €7,234, €16,588 and €7,848, and cost per ACR70 responder €12,593, €29,964 and €33,120 for secukinumab 150mg, secukinumab 300mg and etanercept biosimilar, respectively. Response rates were higher for secukinumab compared to etanercept biosimilar at 24 weeks and cost per responder were consistently lower for secukinumab 150mg for all ACR outcomes and for secukinumab 300mg when considering the most difficult-to-reach outcome." @default.
• W4236430596 created "2022-05-12" @default.
• W4236430596 creator A5008916715 @default.
• W4236430596 creator A5061631144 @default.
• W4236430596 creator A5064645362 @default.
• W4236430596 creator A5073173668 @default.
• W4236430596 date "2018-10-01" @default.
• W4236430596 modified "2023-09-30" @default.
• W4236430596 title "PMS48 - COST PER RESPONDER ANALYSIS FOLLOWING A 24-WEEK PSORIATIC ARTHRITIS TREATMENT WITH SECUKINUMAB VERSUS ETANERCEPT FROM THE PORTUGUESE PAYER PERSPECTIVE" @default.
• W4236430596 doi "https://doi.org/10.1016/j.jval.2018.09.1762" @default.
• W4236430596 hasPublicationYear "2018" @default.
• W4236430596 type Work @default.
• W4236430596 citedByCount "0" @default.
• W4236430596 crossrefType "journal-article" @default.
• W4236430596 hasAuthorship W4236430596A5008916715 @default.
• W4236430596 hasAuthorship W4236430596A5061631144 @default.
• W4236430596 hasAuthorship W4236430596A5064645362 @default.
• W4236430596 hasAuthorship W4236430596A5073173668 @default.
• W4236430596 hasBestOaLocation W42364305961 @default.
• W4236430596 hasConcept C112930515 @default.
• W4236430596 hasConcept C126322002 @default.
• W4236430596 hasConcept C2776260265 @default.
• W4236430596 hasConcept C2777226972 @default.
• W4236430596 hasConcept C2777575956 @default.
• W4236430596 hasConcept C2779786854 @default.
• W4236430596 hasConcept C3019080777 @default.
• W4236430596 hasConcept C59491497 @default.
• W4236430596 hasConcept C71924100 @default.
• W4236430596 hasConceptScore W4236430596C112930515 @default.
• W4236430596 hasConceptScore W4236430596C126322002 @default.
• W4236430596 hasConceptScore W4236430596C2776260265 @default.
• W4236430596 hasConceptScore W4236430596C2777226972 @default.
• W4236430596 hasConceptScore W4236430596C2777575956 @default.
• W4236430596 hasConceptScore W4236430596C2779786854 @default.
• W4236430596 hasConceptScore W4236430596C3019080777 @default.
• W4236430596 hasConceptScore W4236430596C59491497 @default.
• W4236430596 hasConceptScore W4236430596C71924100 @default.
• W4236430596 hasLocation W42364305961 @default.
• W4236430596 hasOpenAccess W4236430596 @default.
• W4236430596 hasPrimaryLocation W42364305961 @default.
• W4236430596 hasRelatedWork W2023378412 @default.
• W4236430596 hasRelatedWork W2624671969 @default.
• W4236430596 hasRelatedWork W2757242335 @default.
• W4236430596 hasRelatedWork W2804271470 @default.
• W4236430596 hasRelatedWork W2811214352 @default.
• W4236430596 hasRelatedWork W2906727963 @default.
• W4236430596 hasRelatedWork W2994641445 @default.
• W4236430596 hasRelatedWork W3111636989 @default.
• W4236430596 hasRelatedWork W4236430596 @default.
• W4236430596 hasRelatedWork W4248008924 @default.
• W4236430596 hasVolume "21" @default.
• W4236430596 isParatext "false" @default.
• W4236430596 isRetracted "false" @default.
• W4236430596 workType "article" @default.